Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
ConclusionReal-world persistence for basal insulin therapy in patients with T2DM was significantly better in those on Gla-300 compared with those on Gla-100 and IDet. A trend to a lower frequency of hospitalization for hypoglycemia and ER visits, whatever the cause, was also observed in patients on Gla-300. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 9, 2020 Category: Endocrinology Source Type: research
Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Na & iuml;ve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
(Source: ClinicoEconomics and Outcomes Research)
Source: ClinicoEconomics and Outcomes Research - June 21, 2020 Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
Exploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir.
CONCLUSIONS: These findings are critical to our understanding of the behaviour of this particular clinically relevant drug, as it will allow the development of future generations of peptide-based therapies with greater clinical efficacy.
PMID: 32446962 [PubMed - as supplied by publisher] (Source: European Journal of Pharmaceutics and Biopharmaceutics)
Source: European Journal of Pharmaceutics and Biopharmaceutics - May 20, 2020 Category: Drugs & Pharmacology Authors: Beji O, Gillis RB, Dinu V, Jiwani SI, Gyasi-Antwi P, Fisk ID, Meal A, Morgan PS, Harding SE, Huang S, Agugini G, Fedele F, Adams GG Tags: Eur J Pharm Biopharm Source Type: research
434: Neonatal hypoglycemia; does basal insulin choice matter?
To compare the basal insulins neutral protamine hagedorn (NPH) and detemir (Levemir) in gestational (GDM) and type 2 diabetes in pregnancy (T2DM), and determine association with neonatal hypoglycemia and pregnancy outcome. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - December 31, 2019 Category: OBGYN Authors: Kafui A. DEMASIO, Michael Richley Tags: Poster Session II Source Type: research
[ASAP] Investigations of Albumin –Insulin Detemir Complexes Using Molecular Dynamics Simulations and Free Energy Calculations
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.9b00839 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - December 16, 2019 Category: Drugs & Pharmacology Authors: Line A. Ryberg* †, Pernille Sønderby†, Jens T. Bukrinski‡, Pernille Harris†, and Gu¨nther H. J. Peters*† Source Type: research
Long-Acting Basal Insulins: A Review of the More Recently Approved Agents
Long-acting basal insulins are used for the management of both type 1 and type 2 diabetes mellitus. Long-acting basal insulins were developed utilizing recombinant DNA technology and have been available since 2000 with the approval of insulin glargine U-100 followed by insulin detemir in 2005. In recent years, diabetes management has become more complex with the approval of insulin glargine U-300 and insulin degludec U-100 and U-200. Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. This r...
Source: Cardiology in Review - August 9, 2019 Category: Cardiology Tags: New Therapy Source Type: research
Real-world experience of using basal insulin analogues in children with type 1 diabetes: is twice-daily dosing of insulin detemir justified?
PMID: 31343144 [PubMed - in process] (Source: Pediatric Endocrinology, Diabetes, and Metabolism)
Source: Pediatric Endocrinology, Diabetes, and Metabolism - July 27, 2019 Category: Endocrinology Authors: Dayal D, Rohilla L Tags: Pediatr Endocrinol Diabetes Metab Source Type: research
Comparison between the effect of regular human insulin and NPH with novo-rapid and levemir insulin in glycemic control in gestational diabetes.
CONCLUSION: Altogether, The Novo-rapid and Levemir Insulin in comparing with the Regular and NPH Insulin were practically advantageous due to the simple using method and short hospitalization period of the patient. Thus, we prefer and suggest this beneficial method (using Novo-rapid and Levemir Insulin) to reach therapeutic goals.
PMID: 31156155 [PubMed - as supplied by publisher] (Source: Human Antibodies)
Source: Human Antibodies - June 4, 2019 Category: Biochemistry Tags: Hum Antibodies Source Type: research
Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different
Abstract
Since the introduction of insulin as a life-saving agent for patients with type 1 diabetes, insulin preparations have evolved to approximate physiologic insulin delivery profiles to meet prandial and basal insulin needs. While prandial insulins are designed to have quick time –action profiles that minimize postprandial glucose excursions, basal insulins are designed to have a protracted time–action profile to facilitate basal glucose control over 24 h. Given that all insulins have the same mechanism of action at the target tissue level, the differences in time–act ion profiles are achieved through differ...
Source: Advances in Therapy - April 27, 2019 Category: Drugs & Pharmacology Source Type: research
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Date: May 6, 2019
Issue #:
1571Summary:
View the Expanded Table: Some Available Insulins (Source: The Medical Letter)
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Jens Juul Holst*
Department of Biomedical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
Researchers have been looking for insulin-stimulating factors for more than 100 years, and in the 1960ties it was definitively proven that the gastrointestinal tract releases important insulinotropic factors upon oral glucose intake, so-called incretin hormones. The first significant factor identified was the duodenal glucose-dependent insulinotropic polypeptide, GIP, wh...
Source: Frontiers in Endocrinology - April 25, 2019 Category: Endocrinology Source Type: research
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
CONCLUSIONS: Switching to insulin degludec from other basal insulins can improve glycaemic control and/or reduce hypoglycaemia risk in people with diabetes (although there was a nonsignificant reduction in HbA1c and hypoglycaemia rates for the neutral protamine Hagedorn group in Type 1 diabetes) under routine care. This article is protected by copyright. All rights reserved.
PMID: 31001865 [PubMed - as supplied by publisher] (Source: Molecular Medicine)
Source: Molecular Medicine - April 17, 2019 Category: Molecular Biology Authors: Knudsen ST, Lapolla A, Schultes B, Tentolouris N, Catarig AM, Wolden ML, Siegmund T Tags: Diabet Med Source Type: research
The Discovery and Development of Liraglutide and Semaglutide
We describe one such approach, albumin binding, and explain how it was applied in the development of the human GLP-1 analog liraglutide once daily and, subsequently, semaglutide once weekly. The pharmacology of these two long-acting GLP-1 analogs, in terms of improving glycemic control, reducing body weight and decreasing cardiovascular (CV) risk, is also reviewed, together with some novel biology. In addition, we describe the importance of accurate target (GLP-1 receptor) tissue expression analysis.
Now an established class of agents, GLP-1-based therapies represent a significant advance in the treatment of T2D. All curr...
Source: Frontiers in Endocrinology - April 11, 2019 Category: Endocrinology Source Type: research
Insulins for Type 2 Diabetes
Date: May 6, 2019
Issue #:
1571Summary:
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is<7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control. (Source: The Medical Letter)
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Detemir Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research
Solution structures of long-acting insulin analogues and their complexes with albumin
The lipidation of peptide drugs is one strategy to obtain extended half-lives, enabling once-daily or even less frequent injections for patients. The half-life extension results from a combination of self-association and association with human serum albumin (albumin). The self-association and association with albumin of two insulin analogues, insulin detemir and insulin degludec, were investigated by small-angle X-ray scattering (SAXS) and dynamic light scattering (DLS) in phenolic buffers. Detemir shows concentration-dependent self-association, with an equilibrium between hexamer, dihexamer, trihexamer and larger species,...
Source: Acta Crystallographica Section D - February 26, 2019 Category: Biochemistry Authors: Ryberg, L.A. S ø nderby, P. Barrientos, F. Bukrinski, J.T. Peters, G.H.J. Harris, P. Tags: SAXS albumin insulin analogues protein complexes rigid-body modelling insulin detemir insulin degludec research papers Source Type: research
